Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

A SHARE OPTION FIRST GRANT UNDER THE 2025 A SHARE OPTION SCHEME

References are made to the announcement of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the "**Company**") dated 22 August 2025 in relation to the proposed adoption of the 2025 A Share Option Scheme and the circular of the Company dated 29 September 2025 (the "**Circular**") in relation to, among other things, the proposed adoption of the 2025 A Share Option Scheme. Unless otherwise defined, capitalised terms used herein shall have the same meaning as those defined in the Circular.

The 2025 A Share Option Scheme was approved by the Shareholders at the EGM held on 23 October 2025. As 6 proposed A Share Option Participants had ceased to be employed by the Group and thus ceased to fall within the scope of A Share Option Participants, on 4 November 2025 the Board resolved to make the A Share Option First Grant of a total of 4,535,100 A Share Options (corresponding to 4,535,100 A Shares, which represent approximately 0.1698% of the total number of Shares of the Company in issue as at 4 November 2025) to 195 A Share Option Participants under the A Share Option Scheme on the same date (i.e. 4 November 2025, being the A Share Option Grant Date of the A Share Option First Grant). The A Share Option Exercise Price of the A Share Option First Grant is RMB27.93 per share.

As certain A Share Option Participants under the A Share Option First Grant are connected persons of the Company, the grant of A Share Options to each such A Share Option Participant constitutes a connected transaction under Chapter 14A of the Hong Kong Listing Rules. However, given that all of the percentage ratios applicable to each such grant are less than 0.1%, each such grant is fully exempt from shareholders' approval, annual review and all disclosure requirements under Chapter 14A of the Hong Kong Listing Rules.

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
4 November 2025

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong and Mr. Wang Kexin; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* *For identification purposes only*